Depression follow-up monitoring with the PHQ-9: an open cluster-randomised controlled trial.
Kendrick T, Dowrick C, Lewis G, Moore M, Leydon GM, Geraghty AW, Griffiths G, Zhu S, Yao GL, May C, Gabbay M, Dewar-Haggart R, Williams S, Bui L, Thompson N, Bridewell L, Trapasso E, Patel T, McCarthy M, Khan N, Page H, Corcoran E, Hahn JS, Bird M, Logan MX, Ching BCF, Tiwari R, Hunt A, Stuart B.
Kendrick T, et al. Among authors: zhu s.
Br J Gen Pract. 2024 Jun 27;74(744):e456-e465. doi: 10.3399/BJGP.2023.0539. Print 2024 Jul.
Br J Gen Pract. 2024.
PMID: 38408790
Free PMC article.
Clinical Trial.
The secondary outcomes were as follows: BDI-II at 26 weeks; Work and Social Adjustment Scale (WSAS) and EuroQol EQ-5D-5L quality of life at 12 and 26 weeks; antidepressant treatment; mental health and social service contacts; adverse events, and Medical Interview Satisfact …
The secondary outcomes were as follows: BDI-II at 26 weeks; Work and Social Adjustment Scale (WSAS) and EuroQol EQ-5D-5L quality of l …